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ABSTRACT
MicroRNAs are differentially expressed in breast cancer cells and have been 
implicated in cancer formation, tumour invasion and metastasis. We investigated 
the miRNA expression profiles in the developing mammary gland. MiR-137 was 
expressed prominently in the developing mammary gland. When the miR-137 was 
over-expressed in the embryo, the mammary epithelium became thickened. Moreover, 
genes associated with mammary gland formation such as Tbx3 and Lef1 were not 
expressed. This suggests that miR-137 induces gland formation and invasion. When 
miR-137 was over-expressed in MDA-MB-231 cells, their ability to form tumours in 
adult mice was significantly reduced. These data support miR-137 decides epithelial 
cell behavior in the human breast cancer. It also suggests that miR-137 is a potential 
therapeutic target for amelioration of breast cancer progression.
INTRODUCTION
Mammary gland development in mouse embryos is 
used as a model for breast cancer and can be divided into 
a series of stages [1-3]. In the initiation stage (in E10.5 
mouse embryos), bilateral mammary lines are formed and 
epidermal cells of the mammary line become columnar 
and multilayered, defining the mammary ridge. At E11.5, 
five pairs of mammary placodes form at specific locations 
along the mammary line and these placodes then begin 
to invade the underlying mesenchyme (E12.5) to form a 
spherical epithelial bud enveloped by dense mammary 
mesenchyme and connected to the epidermis by a short 
stalk (E13.5) [4]. Subsequently, the epithelial bud grows 
and undergoes branching morphogenesis in female mice. 
Many genes expressed in the developing mouse mammary 
gland are also expressed in adult human breast cancer, 
including genes encoding molecules involved in signaling 
e.g. the estrogen receptor is expressed in the mesenchyme 
surrounding the invasive mammary epithelial bud [5] 
and various transcription factors [6-10]. For example, 
Tac1, the gene encoding Tachykinin-1, the precursor 
protein for neuroendocrine peptides, is expressed in the 
mammary mesenchyme during embryonic development 
[11-13] and the level of Tac1 expression in breast cancers 
is directly proportional to their aggressiveness [14, 
15]. Another example is the GATA family zinc-finger 
transcription factor, GATA3, a crucial regulator of luminal 
differentiation during mammary gland development [16, 
17] which is expressed within invasive breast carcinomas 
[18].
Alterations in several genes, including those 
encoding microRNAs (miRNAs), accumulate in cancer 
by a complex and multistep process [19]. MiRNAs are 
19- to 25-nucleotide single-stranded RNA molecules 
that function as post-transcriptional regulators of target 
Oncotarget22049www.impactjournals.com/oncotarget
genes expression [20, 21]. Recent studies have reported 
that miRNAs may act as either tumour suppressors or 
oncogenes [22, 23] and there is interest in identifying 
miRNAs associated with breast cancer as they could be 
novel therapeutic targets. Here we investigated which 
miRNAs are expressed in the early development of mouse 
mammary glands by comparing the 3rd mammary gland 
and the inter mammary gland region from E13.5 mouse 
embryos. We found that miRNA-137 (miR-137) is highly 
expressed in the 3rd mammary gland at E13.5 and over-
expressing it in the flank region of developing mouse 
embryos perturbed invasion of the epithelial mammary 
bud.
 Down-regulated miR-137 has been observed in 
various cancers such as colorectal cancer, gastric cancer, 
oral cancer, and squamous cell carcinoma of the head and 
neck [24-27]. A recent study also reported that miR-137 
impairs proliferation and migration of cells of a breast 
cancer cell line by targeting expression of the nuclear 
receptor estrogen-related receptor alpha (ERRα) [28], 
suggesting that miR-137 may suppress the formation of 
breast cancer. To confirm this possibility in vivo, we over-
expressed miR-137 in cells of a breast cancer cell line, 
then inoculated them into nude mice and found that their 
ability to form tumours was reduced.
The outcomes of this study reveal that miR-137 not 
only perturbs embryonic mammary gland development 
but also inhibits tumour formation by human breast cancer 
cells. These results bolster the idea that the embryonic 
mouse mammary gland is a good model for human breast 
cancer.
RESULTS 
Microarray profiling of embryonic mouse 
mammary glands
To identify miRNAs expressed in the embryonic 
mouse mammary gland during invagination of the 
epithelial bud, we used miRNA microarrays to compare 
the 3rd mammary gland and inter mammary gland 
flank region dissected from E13.5 mouse embryos 
(Supplementary Figure S1A-S1C). This analysis showed 
that expression of many miRNAs is correlated to 
mammary gland development (Figure 1A and 1B). Among 
these, the expression level of miR-137 was increased 
about 30 fold in the 3rd mammary gland compared to inter 
mammary gland region (red box in Figure 1B). This high 
level of expression in the 3rd mammary gland forming 
region was confirmed by carrying out in situ hybridization 
using a miR-137 locked nucleic acid (LNA) probe to 
detect miR-137 transcripts (Supplementary Figure S1D). 
We also carried out further microarray analysis using 
tissue dissected from mouse embryos in the same way to 
screen for protein-coding genes differentially expressed 
in the developing gland. As expected, we found many 
genes already known to be highly expressed in developing 
mouse gland at similar stages [5]. For example, ER1 and 
Gata3 were highly expressed in 3rd mammary gland 
compared to the intermammary gland region (Figure 1C). 
The gene that we found to be most highly expressed in 
the 3rd mammary gland at E13.5 was Tac1 (red boxes in 
Figure 1C).
Relationship between miR-137 and mammary 
gland development
To investigate the function of miR-137 in mouse 
mammary gland development, we over-expressed 
miR-137 using a lentiviral system in the flank region 
of E11.0 mouse embryos and then cultured the flank 
for 72 h. As controls, we over-expressed scrambled 
miRNA. The lentiviral system also incorporated an 
EGFP cassette and successful over-expression of miR-
137 or the control scrambled miRNA was confirmed by 
immunohistochemistry (IHC) using EGFP antibody and 
real-time quantitative polymerase chain reaction (RT-
qPCR) (Figure 2C and 2D; Supplementary Figure S2A). 
In the controls, well-developed mammary buds were 
observed. With the over-expression of miR-137, thickened 
epithelium was observed in mammary placode region. 
However, this enlarged epithelium showed different cell 
morphology from normal mammary placode cells and 
they did not protrude into the underlying mesenchyme 
to give a spherical bud (compare Figure 2A and 2C 
with Figure 2B and 2D; see also for example Figure 2O 
versus 2P). To determine whether miRNA-137 inhibits or 
simulates expression of genes involved in mammary gland 
formation, we applied miR-137 to cultured mouse flanks 
and examined expression of Gata3, T-box transcription 
factor Tbx3, Tac1, and Lef1 (lymphoid enhancing factor 
1) (Figure 2E-2T). 
Surface views of the embryos showed that the Gata3 
expression pattern was ring shaped, in the mammary 
glands at E12.5. However, at E13.5, expression of Gata3 
was seen in entire mammary gland region (compare 
Figure 2E and 2G with Supplementary Figure S3S and 
V). Gata3 expression pattern was altered by miR-137 
over-expression. Mesenchymal expression of Gata3 was 
induced but epithelial expression was reduced by miR-
137 over-expression (Figure 2F and 2H). Gata3 was 
expressed in the center of mammary epithelial, surface 
ectoderm and mammary mesenchyme just beneath 
epithelium of mammary bud in control (Figure 2G). 
However, Gata3 expression was lost its typical pattern in 
mammary epithelium and surface ectoderm after miR-137 
over-expression (Figure 3H). Gata3 was observed in the 
flank mesenchyme besides the mammary bud (Figure 2F) 
extending both ventrally and dorsally after miR-137 over-
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Figure 1: Heat-map of 3rd mammary gland and inter mammary gland region miRNA expression illustrating cluster-
analysis of the expression data. A., B. The signal intensity converted to log2 is reflected in the color scale such that dark green, green 
and red show low, medium and strong miRNA expression, respectively. The dendrogram on the left shows hierarchical similarity. C. 
Microarray data sorting for protein-coding genes related to mammary gland development.
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Figure 2: Function of miR-137 during mammary gland development. A., B. HE staining of sections of mammary glands that 
developed after miR-137 over-expression, shows that normal invasion has not taken place although the placode has thickened. C., D. EGFP 
IHC indicates that scrambled miRNA and miR-137 have been successfully over-expressed. E.-H. Gata3 expression is disrupted by over-
expressed miR-137. I.-L. MiR-137 over-expression alters Tac1 expression. (M-T) Expression patterns of the mammary gland markers, 
Tbx3 and Lef1, are changed after miR-137 treatment. Arrows, mammary bud. Arrowheads, ectopic Tac1 expression. Asterisk, disrupted 
Tac1 expression region ; FL, fore limb; HL, hind limb; Scale bar, A-D, G, H, K, L, O, P, S, T, 100 μm; E, F, I, J, M, N, Q, R, 1 mm.
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expression (Figure 2H).
Tac1 is also known to be expressed only in 
mammary mesenchyme around in the developing 
mammary bud (Supplementary Figure S3G-S3L; ref 11-
13) and this expression pattern was not changed by over-
expression of scrambled miRNA (compare Figure 2I, 2K 
and Supplementary Figure S3G, S3J). Ectopic expression 
of Tac1 was detected between 3rd and 4th mammary 
gland after miR-137 over-expression (Figure 2I and 2J 
arrowheads). In transverse section showed that Tac1 was 
expressed in mesenchyme under surface ectoderm region 
but it was not expressed mesenchyme below mammary 
bud after miR-137 over-expression (Figure 2K and 2L 
asterisks).
Wnt signaling correlates expression of the 
transcription factor, Tbx3, which is essential for epithelial-
mesenchymal interaction with Lef1 during early mammary 
gland development [30, 31]. In control, Tbx3 was 
expressed in mammary bud, mammary gland mesenchyme 
and dorsal part of flank in mouse embryo (Figure 2M and 
2O). After miR-137 over-expression, Tbx3 expression 
pattern was similar as control in surface view of the dorsal 
part embryo flank (Figure 2N). However, transverse 
section showed that Tbx3 was completely obliterated in 
the mammary epithelium (Figure 2P). In addition, Tbx3 
expression was induced in mammary mesenchyme and 
dermal mesenchyme region in dorsal part of flank (Figure 
2P).
In the controls, expression of the Lef1 was observed 
in mammary epithelium from initiation (E10) to bud 
stage (E13) [31]. It was clearly observed in mammary 
epithelial buds in control (Figure 2Q and 2S). However, 
Lef1 expression was detected in broad region of mammary 
gland than control after miR-137 over-expression (Figure 
2R). Moreover, Lef1 was not expressed in mammary 
epithelium except surface ectoderm and the margin of 
the enlarged mammary placodes between mammary 
epithelium and mesenchyme (Figure 2T). In addition, 
ectopic Lef1 expression was observed in mesenchyme 
around mammary gland after miR-137 over-exrpression 
(Figure 2T).
All these results indicate that over-expression of 
miRNA-137 suppresses development of the mammary 
gland in mouse embryos.
In vivo tumour formation assay after miR-137 
over-expression
Recent work has shown that miR-137 impairs 
proliferation and migration of MDA-MB-231 human 
breast cancer cells in culture [28]. In order to investigate 
the relationship between miR-137 and breast tumour 
growth in vivo, MDA-MB-231 cells over-expressing 
miR-137 were inoculated subcutaneously (SC) in nude 
mice (n = 34) and formation of tumours were monitored 7 
weeks later. Over-expression of miR-137 in the cells was 
confirmed by RT-qPCR (Supplementary Figure S2B). As 
a control, MDA-MB-231 cells over-expressing scrambled 
miRNA were inoculated (n = 16). The tumours formed 
by miR-137 over-expressing cells were noticeably smaller 
than those formed by cells transfected with the scrambled 
miRNA (Figure 3A). In fact, in 3 of the mice injected 
with MDA-MB-231 cells over-expressing miR-137 no 
tumours formed at all. In order to quantitate these results, 
we measured tumour weight and volume. Both weight 
and volume of tumours developing from miR-137 over-
expressing cells were significantly reduced compared with 
tumours developing from cells over-expressing scrambled 
miRNA (Figure 3B and 3C). Thus, these results showed 
that miR-137 can suppress tumour formation in vivo.
Expression pattern of angiogenesis and tumour 
suppressor markers after miR-137 overexpression
To explore the mechanisms involved in suppressing 
tumour formation when miR-137 is over-expressed in 
MDA-MB-231 cells, we performed IHC to monitor cell 
proliferation, angiogenesis and expression of tumour 
suppressors. Cell proliferation was reduced in the tumours 
formed by miR-137 over-expressing cells. A large number 
of Ki67-positive proliferating cells were observed in 
tumours formed by cells expressing the scrambled miRNA 
compared to tumours formed by cells over-expressing 
miR-137 (Supplementary Figure S4A-S4D). The number 
of Ki67-positive cells was counted in scramble and miR-
137 over-expression group. The numbers of Ki67-positive 
cells were 38.57 cells/100 X 100 µm and 14.14 cells/100 X 
100 µm in scramble miRNA and miR-137 over-expressing 
group, respectively (Supplementary Figure S4E).
In addition, we found that angiogenesis was 
markedly reduced after miR-137 over-expression. 
Staining for the sinusoidal endothelial cell marker CD31 
indicated that there were a smaller number of blood 
vessels in the tumours made by miR-137 over-expressing 
MDA-MB-231 cells (Figure 4A-4F) and furthermore the 
expression of vasculogenesis markers, VEGF and vWF 
were dramatically reduced (Figure 4G-4L; Figure 4M-
4R). On the other hand, expression of known tumour 
suppressors, Runx3 and p53, was increased in the tumours 
formed by miR-137 over-expressing cells (Figure 4S-
X; Figure 5A-5C). The area of CD31, VEGF, vWF and 
Runx3 expression in the scramble miRNA and miR-137 
over-expression group was measured (n = 7 for each). 
The CD31, VEGF and vWF positive area was reduced in 
the miR-137 over-expression group than in those treated 
with scramble miRNA treated group. Runx3 expression 
region was increased in miR-137 treated group compared 
to control group (Figure 4Y).
 Moreover, the cells in the tumours formed from 
miR-137 over-expressing cells induced the epithelial 
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Figure 3: Tumour formation after SC inoculation of MDA-MB-231 cells over-expressing scrambled miRNA (controls) 
or over-expressing miR-137. A. Cells over-expressing miR-137 form smaller tumours than cells over-expressing scrambled miRNA. 
B. Tumour weight is markedly reduced after miR-137 over-expression C. as is tumour volume compared  to controls. Scale bar, 1 cm.
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marker E-cadherin expression (Supplementary Figure 
S5A-S5F) but mesenchymal marker, Vimentin expression 
was reduced compare to control (Supplementary Figure 
S5G-S5L). 
MiR-137 binding to Tac1 was examined by 
measuring luciferase activity with a dual-luciferase assay 
vector containing cloned 3’UTR of Tac1 transcripts 
(Figure 5D). Wild-type (WT) Tac1 reporters showed an 
inhibition of Renilla luciferase activity compared with 
the mutant reporter (Mut), with mismatched sequences 
inserted into the seed sequences of the predicted miR-137 
binding site (Figure 5D). Luciferase assay results indicate 
that Tac1, which confers a poor prognosis in breast cancer 
[14,15], was the directly correlated to miR-137 (Figure 
5D).
DISCUSSION
From screens of tissue from mouse embryos for 
miRNAs differentially expressed in the developing 
mammary gland, we identified miR-137 was highly 
expressed. We also identified, via screening of the same 
tissues, that many protein-coding genes were already 
known to be expressed in the developing mammary gland 
and in breast tumours. Upon over-expression of miR-137 
in mouse embryo flank during organ culture, the mammary 
epithelium thickened but it did not express several key 
Figure 4: IHC of vasculogenesis and tumour suppressor markers after miR-137 over-expression. A.-F. Sinusoidal 
endothelial cell marker CD31 is reduced after miR-137 over-expression. G.-L. Over-expressed miR-137 inhibits VEGF expression. M.-
R. vWF expression is decreased in breast cancer after over-expression of miR-137 in MDA-MB-231. S.-X. Tumour suppressor Runx3 
expression is substantially increased after miR-137 treatment. Y. The area of CD31, VEGF, vWF and Runx3 expression in the scramble 
miRNA and miR-137 over-expression group (n = 7 for each). IHC staining positive areas Scale bar, 100 μm.
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genes known to be required for gland development and it 
also failed to invaginate into the underlying mesenchyme. 
MiR-137 is also highly expressed in an epithelial cell 
line derived from the adult human breast. When we over-
expressed miR-137 in this breast cancer cell line, tumour 
formation in vivo was suppressed.
We identified miR-137 as a miRNA highly 
expressed in the developing mouse mammary gland at 
a stage when the mammary placode has invaginated the 
underlying mesenchyme to form a spherical bud. Our 
data and that of others [5] reveal that around this stage in 
development, many genes encoding proteins known to be 
associated with breast cancer are expressed in the gland. 
Thus, the molecular analysis of the mouse embryonic 
mammary gland is a good strategy for identifying genes 
that are potentially involved in breast cancer and any 
miRNAs identified from the mammary gland are good 
candidates for miRNAs associated with breast cancer.
ER1, GATA3 and Trps1 are among the genes that 
are highly expressed in the E13.5 mouse mammary gland 
and have also been implicated in human breast cancer 
[5,16-18]. These genes were also identified by microarray 
analysis of E12.5 mammary glands. In addition, our 
analysis identified genes encoding proteins involved in 
retinoic acid signaling which appears to be involved in 
gland initiation [32]. Some genes identified are expressed 
in the mesenchyme and some in the epithelial bud and 
it is well-established that there are complex reciprocal 
signaling correlations between these tissues during normal 
development. 
Our functional analysis suggests that miR-137 is 
involved in modulating early stages of mammary gland 
formation in the embryo especially invasion. When miR-
137 is over-expressed, mammary placode formed and 
thickened but failed to invade the underlying mesenchyme 
and did not express either Tbx3 or Lef1 in mammary 
epithelium. Tbx3 mutations are found in Ulnar mammary 
syndrome in human patients, which is characterized by 
mammary gland hypoplasia [33, 34]. In Tbx3 knockout 
(KO) mouse embryos, mammary placode do not form and 
expression of Lef1 is absent [34]. Lef1 expression is one 
of the earliest molecular markers of placode formation and 
is also maintained in the epithelial cells during invasion 
of the epithelial bud. Thus, the failure of the mammary 
placode invagination by loss of Tbx3 and Lef1 after miR-
137 over-expression suggests that miR-137 correlated the 
early stages of mammary gland development. Tac1 and 
Gata3 genes whose expression is also altered by over-
expression of miR-137 are also detected at early bud 
stages. Moreover, luciferase assay results indicate that 
Tac1, which confers a poor prognosis in breast cancer [14, 
15], was the direct target of miR-137. These data suggest 
that miR-137 is a potential therapeutic target for breast 
cancer by controlling of Tac1 expression.
In breast cancer cells, miR-137 has been shown to 
target expression of ERRα [28]. It is not clear whether 
ERRα could be the target of miR-137 in the developing 
mouse mammary gland. Interestingly, ER1 is expressed in 
Figure 5: MiR-137 induces p53 expression in mammary gland tissue and breast cancer. A.-C. Expression level of p53 is 
increased in mammary gland tissue and MDA-MB-231 cells after over-expressing miR-137. D. A luciferase assay result indicating that 
Tac1 is a direct target of miR-137.
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the mesenchyme surrounding the mammary bud at E12.5 
[5] and is a target of miR-206, which is also expressed 
in the mesenchyme at E11.5 and E12.5 (earlier than 
miR-137) but not at E13.5 [35]. When miR-206 was 
over-expressed in the same flank culture system used 
here, mammary placode development was very severely 
retarded; the placode formed but did not thicken [35]. This 
is consistent with miR-206 having a function at a slightly 
earlier stage in mammary gland development than miR-
137.
Our results also showed that over-expression of 
miR-137 reduced tumour formation in vivo. Interestingly, 
we observed that cell proliferation of subcutaneously 
inoculated breast cancer cells was reduced when miR-137 
was over-expressed. Moreover, epithelial-mesenchymal 
transition (EMT) was inhibited in the tumours formed 
from miR-137 over-expressing MDA-MB-231 cells. 
These results indicate that miR-137 have multiple 
tumour suppress function including prevention of the cell 
proliferation, epithelial invasion and EMT.
Our focus on miR-137 initially arose from screening 
for genes differentially expressed in embryonic mammary 
glands and this shows how the study of the developing 
embryonic mammary gland can provide new perspectives 
on breast cancer.
MATERIALS AND METHODS
All experiments were performed according to 
the guidelines of the Intramural Animal Use and Care 
Committee of Yonsei University College of Dentistry.
Animals
Adult Institute of Cancer Research Research; 
Caesarian Derived-1 (ICR; CD-1) mice were housed in 
a temperature-controlled room (22°C) under artificial 
illumination (lights on from 0500 to 1700 hours) and 
55% relative humidity. The mice had access to food and 
water ad libitum. Embryos were obtained from time-mated 
pregnant mice. E0 was designated as the day a vaginal plug 
was confirmed. Embryos at developmental stages E11.0, 
E12.5 and E13.5 were used in this study. To study tumour 
formation, subcutaneous (SC) inoculation of 2.0X106 
MDA-MB-231 cells was performed in the BALB/c 
nude mice (Orientbio, Korea). No immunosuppressive 
medication was used. Tumour size was measured seven 
weeks after SC inoculation. The host nude mice were 
sacrificed, and tumours were dissected for analysis.
MiRNA microarray analysis
For mammary gland miRNAs, the synthesis of target 
miRNA probes and hybridization were performed using 
Agilent’s miRNA Labelling Reagent and Hybridization 
kit (Agilent Technology, USA) according to the 
manufacturer’s instructions. Briefly, 100 ng of total RNA 
from each region (the 3rd mammary gland and the inter-
mammary gland region) at E13.5 was dephosphorylated 
with ~15 Units of calf intestine alkaline phosphatase 
(CIP), followed by RNA denaturation with ~40% DMSO 
and a 10 min incubation at 100 °C. Dephosphorylated 
RNA was ligated with pCp-Cy3 mononucleotide and 
purified with MicroBioSpin 6 columns (Bio-Rad, USA). 
After purification, labelled samples were resuspended 
with Gene Expression blocking Reagent and Hi-RPM 
Hybridization buffer, followed by boiling for 5 min at 100 
°C and 5 min chilled on ice. Finally, denatured labelled 
probes were pipetted onto the assembled Agilent miRNA 
Microarray (15K) and hybridized for 20 hours at 55 °C 
with rotation at 20 rpm in an Agilent Hybridization oven 
(Agilent Technology, USA). The hybridized microarrays 
were washed as the manufacturer’s washing protocol 
(Agilent Technology, USA). Location of array raw data; 
GEO (http://www.ncbi.nlm.nih.gov/geo /query/acc.
cgi?acc=GSE66546)
Data acquisition and analysis
The hybridized images were scanned using Agilent’s 
DNA microarray scanner and quantified with Feature 
Extraction Software (Agilent Technology, Palo Alto, CA). 
All data normalization and selection of fold-changed 
genes were performed using GeneSpringGX 7.3 (Agilent 
Technology, USA). The averages of normalized ratios 
were calculated by dividing the average of normalized 
signal channel intensity by the average of normalized 
control channel intensity. Functional annotation of genes 
was performed according to the Gene OntologyTM 
Consortium (http://www.geneontology.org/index.shtml) 
by GeneSpringGX 7.3.
Lentivirus production by transfecting 293T cells
We used miExpressTM precursor miRNA expression 
clone (GeneCopoeiaTM, USA) for miR-137 over-
expression in mouse embryo flank and MDA-MB-231 
cell. This clone is pEZX-MR04 vector system which 
carries EGFP and CMV promoter. The pEZX-MR04 
vector confers resistance to puromycin (5-15 μg/ml) in 
transduced or transfected cells. The minimum antibiotic 
concentration to use is the lowest concentration that kills 
100% of the cells in 3-6 days from the start of antibiotic 
selection. Finally we used 10 μg/ml purimycin for 
transfection of lentivirus production. Lentiviral production 
was carried out by transfecting human embryonic kidney 
293T cells with lentivital and packaging vectors. For viral 
tittering, 5 X 104 293T cells were seed into 24-well culture 
plate with DMEM (10% FBS, 1% pen-strep) and counted 
the EGFP expressing cells or colonies of cells. EGFP 
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positive colonies X 125 (dilution factor) X 40 = 2.76 X 
105 TU/mL. For each 100 mm dish, helper plasmid pCD-
NL/BH*ΔΔΔ 3 µg, envelope pLTR-G 300 ng, target miR-
137 expressing lentivirus DNA 3 µg were mixed in 500 µl 
transfection reagent FuGENE HD (Roche). This mixture 
was incubated at room temperature for 20 min, and then 
added to 293T cells. The medium was changed after 4 h 
into culture medium containing 30% FBS. The resulting 
supernatant was collected 48 h, filtered through syringe 
driven filter Unit 0.45µg (Millipore, Cat No. SLHV 033 
RS) and concentrated by Amicon Ultra-15 Centrifugal 
Filter Devices (Millipore, Cat No. UFC910024). Virus 
medium was used for in vitro organ and breast cancer cell 
culture.
Over-expression of miR-137 in in vitro organ 
culture and breast cancer cells
During cell culture (MDA-MB-231), miR-137 
expressing lentiviral vector was transduced into cells. 
Concentrated miR-137 expressing lentivirus was added 
1% (v/v) in culture medium containing polybrene (Santa 
Cruz Biotechnology). ICR mouse embryos were isolated at 
E11.0 and placed in culture medium (BGJb; Sigma, USA). 
The culture medium was supplemented with 20 μg/mL 
(v/v) ascorbic acid (Sigma, USA) and 1% (v/v) penicillin/
streptomycin. Individual embryos were dissected into 
left and right halves using fine tungsten needles to 
bisect the neural tube. The left flank was designated the 
experimental tissue, and the right acted as control. Each 
flank was placed onto filter membranes (Track-etch, 1.0 
μm pore; Whatman Nuclepore) that were supported on 
stainless steel grids in sterile culture dishes. Tissues were 
cultured in the air–medium interface at 37 °C and 5% CO2 
for 12 h and 48 h by using a slight modification of the 
culture method reported by Trowell [29]. MDA-MB-231 
human breast cancer cells were cultured in MEM (Lonza) 
supplemented with 10% (v/v) fetal bovine serum (Gibco), 
100 unit/ml penicillin and 100 ug/ml streptomycin. 
Cells were grown to confluence at 37 °C in a humidified 
atmosphere containing 5% CO2 in air.
In situ hybridization 
Cultured specimens were fixed overnight in 
4% paraformaldehyde in phosphate buffered saline 
(PBS). For in situ hybridization, the specimens were 
treated with 20 μg/mL proteinase K for 5 min at room 
temperature [30]. Antisense RNA probes were labeled 
with digoxigenin (Roche). MiR-137 locked nucleic acid 
(LNA) modified probe was synthesized in Exiqon. After in 
situ hybridization, the specimens were cryosectioned at a 
thickness of 12 μm. At least 20 specimens were examined 
for each stage.
Histology and IHC 
Samples were fixed in 4% paraformaldehyde in 
phosphate buffered saline (PBS) and then embedded in 
paraffin using standard procedures. Serial paraffin sections 
(4-μm thickness) were prepared, and individual slides were 
stained with haematoxylin and eosin. Antigen retrieval 
was achieved by citrate buffer, pH 6.0. After antigen 
retrieval, immunohistochemical analyses were performed 
using the DakoCytomation Envision System (using 
horseradish peroxidase with diaminobenzidine enhancer) 
(Dako, CA, USA) according to the manufacturer’s 
instructions. The following primary antibodies were 
used for immunostaining or immunofluorescence: Ki67 
(Thermo Scientific, USA), EGFP (Novus, USA), CD31 
(BD Pharmingen, USA), vWF (Millipore, USA), VEGF 
(Santa Cruz Biotechnology, Inc., USA), Runx3 (Abcam, 
USA), E-cadherin (R&D systems, USA), and Vimentin 
(Thermo Scientific, USA). Alexa Fluor-conjugated 
secondary antibodies (Invitrogen, Carlsbad, CA, USA) 
were used for immunofluorescent staining. The stained 
sections were examined with a Leica MD5500D and a 
Zeiss LSM700.
Quantification of Ki67-positive cells
Ten slides that contained five sections each were 
used to determine the number of total cells and Ki67-
positive cells, and 15 sections were chosen at random from 
the 10 slides. The number of cells was counted in an area 
of 100 X 100 µm. After counting the proliferating cells, 
we corrected the counting results using Abercrombie’s 
method [36]. 
The equations used is
 
P is the average number of nuclear points per 
section, A the crude count of number of nuclei seen in the 
section, M the thickness of the section and L is the average 
length of the nuclei. Data were expressed as the mean ± 
S.D.
Evaluation and statistics of IHC staining
Pictures were taken by the confocal microscope 
(Carl Zeiss LSM700, Germany). The positive pixels of 
images were counted by the software Leica Application 
(Leica Microsystems, Germany). All parameters of the 
image acquisition were kept the same to allow comparison. 
Data were expressed as mean ± SD. The mean expression 
levels were compared between the experimental and 
control groups using ANOVA (SPSS 10.0), with a 
probability value of P < 0.05 (Tukey’s HSD test) being 
considered statistically significant.
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Luciferase assay
For the luciferase assay, the full length 3’UTRs 
of Tac1 genes (from 686nt to 1230nt of mRNA) were 
amplified from E13.5 mouse genomic DNA by PCR using 
sense and antisense primers carrying an XhoI restriction 
site and a NotI restriction site, respectively. The 3’UTR of 
the Tac1 gene was then cloned downstream of the Renilla 
luciferase gene in the psiCHECKTM-2 vector (Promega) 
between the XhoI and NotI sites. A mutant Tac1 3’UTR 
was synthesized using the QuikChange Lightning Multi 
Site-Directed Mutagenesis Kit (Agilent Technologies). 
Primer sequences used for cloning and mutagenesis 
are reported in Supplementary Figure S6. Cos-7 cells, 
a fibroblast-like cell line derived from monkey kidney 
tissue, were cultured in RPMI 1640 Medium (Gibco) 
supplemented with 10% (v/v) fetal bovine serum (Gibco) 
and 100X GlutaMaxTM-I (Gibco), without penicillin and 
streptomycin antibiotics. After cells grew to 80-90% 
confluence, wild type (psiCHECKTM-2 Tac1) or mutant 
(Mut) reporter vectors were co-transfected into Cos-
7 cells with or without a miR-137 expressing lentiviral 
vector using FuGENE®H (Promega) and salmon sperm 
DNA (ssDNA, Sigma). A scrambled miRNA was used 
as control. Renilla and Firefly luciferase activities were 
measured 24 h and 48 h after transfection. Firefly and 
Renilla luciferase activities were measured using the dual-
luciferase reporter system (Promega) on a GLOMAXTM 
20/20 Luminometer (Promega). The data generated 
were expressed as relative ratios by normalizing Renilla 
luciferase readings to Firefly luciferase readings. All 
transfection experiments were performed in triplicate.
Western blotting analyses
Mammary gland tissue and MDA-MB-231 
cells treated with the scrambled miRNA and miR-
137-expressing lentiviral vectors underwent lysis by 
sonication (Nextadvance) in radio-immunoprecipitation 
assay (RIPA) buffer (50 nM Tris pH 7.5, 150 mM NaCl, 
1 mM EDTA, 1% Triton X-100). Anti-p53 (Santa Cruz 
Biotechnology, Inc., USA) antibody was used. Horseradish 
peroxidase conjugated secondary antibodies (Santa Cruz 
Biotechnology, Inc., USA) were used, and the protein 
bands were visualized by enhanced chemiluminescence 
(Amersham Biosciences, USA). α-tubulin expression 
served as an internal control.
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